Patents by Inventor Fabio Vita

Fabio Vita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uranium-chelating peptides and uses thereof
    Patent number: 9321849
    Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: April 26, 2016
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Claudio Vita, Mireille Sauvage-Vita, Fabio Vita, Elena Vita, Loïc Le Clainche, Véronique Monjardet
  • CD4 mimic peptides and their uses
    Patent number: 8354498
    Abstract: An isolated peptide comprising the sequence (I): TPA-Asn-Leu-His-Phe-Cys-Gln-Leu-Xaaa-Cys-Lys-Ser-Leu-Gly-Leu-Leu-Gly-Arg-Cys-Xaab-Xaac-Xaad-Xaae-Cys-Ala-Cys-Val-NH2, wherein: TPA represents thiopropionic acid; Xaaa represents Arg, Lys; Xaab represents Ala, Arg; Xaac represents a D-amino acid; Xaad represents Thr, Ser, Asn; Xaae represents phenylalanine or a phenylalanine derivative having the structure (II), where A is absent or represents S, O, NH or CH2, B is absent or represents a C1 to C6 branched or straight-chain alkyl, and R represents a C3 to C6 alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, cycloheterocyloalkenyl, aryl, or heteroaryl, and the use of the peptide for manufacturing anti-HIV therapeutic or vaccine compositions are disclosed herein.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: January 15, 2013
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Loïc Martin, François Stricher, Anne Descours, Laurence Morellato, Mireille Sauvage-Vita, Fabio Vita, Elena Vita
  • URANIUM-CHELATING PEPTIDES AND USES THEREOF
    Publication number: 20110093964
    Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
    Type: Application
    Filed: December 28, 2010
    Publication date: April 21, 2011
    Inventors: Claudio Vita, Mireille Sauvage-Vita, Fabio Vita, Elena Vita, Loïc Le Clainche, Véronique Monjardet
  • Uranium-chelating peptides and uses thereof
    Patent number: 7888311
    Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: February 15, 2011
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Claudio Vita, Mireille Sauvage-Vita, legal representative, Fabio Vita, legal representative, Elena Vita, legal representative, Loïc Le Clainche, Véronique Monjardet
  • Chimeric HIV-1 Glycoproteins and Their Biological Applications
    Publication number: 20100303858
    Abstract: The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response. Application for the preparation of vaccinal and pharmaceutical composition.
    Type: Application
    Filed: November 28, 2006
    Publication date: December 2, 2010
    Inventors: Francisco Veas, Claudio Vita, Mireille C. Sauvage, Fabio Vita, Elena Vita, Loic Martin, Dorothy Bray, Kadija Benlhassan-Chahour
  • Uranium-chelating peptides and uses thereof
    Publication number: 20100015056
    Abstract: The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence.
    Type: Application
    Filed: July 1, 2004
    Publication date: January 21, 2010
    Inventors: Claudio Vita, Mireille Sauvage-Vita, Fabio Vita, Elena Vita, Loïc Le Clainche, Véronique Monjardet
  • CD4 MIMIC PEPTIDES AND THEIR USES
    Publication number: 20090285798
    Abstract: An isolated peptide comprising the sequence (I): TPA-Asn-Leu-His-Phe-Cys-Gln-Leu-Xaaa-Cys-Lys-Ser-Leu-Gly-Leu-Leu-Gly-Arg-Cys-Xaab-Xaac-Xaad-Xaae-Cys-Ala-Cys-Val-NH2, wherein: TPA represents thiopropionic acid; Xaaa represents Arg, Lys; Xaab represents Ala, Arg; Xaac represents a D-amino acid; Xaad represents Thr, Ser, Asn; Xaae represents phenylalanine or a phenylalanine derivative having the structure (II), where A is absent or represents S, O, NH or CH2, B is absent or represents a C1 to C6 branched or straight-chain alkyl, and R represents a C3 to C6 alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, cycloheterocyloalkenyl, aryl, or heteroaryl, and the use of the peptide for manufacturing anti-HIV therapeutic or vaccine compositions are disclosed herein.
    Type: Application
    Filed: May 9, 2007
    Publication date: November 19, 2009
    Inventors: Claudio Vita, Mireille Sauvage-Vita, Fabio Vita, Elena Vita, Loïc Martin, Francois Stricher, Anne Descours, Laurence Morellato